[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dyslipidemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dyslipidemia":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,56,0,25,[9,52,80,117,141,168,200,235,274,301,333,363,383,411,439,464,483,508,528,549,577,607,633,656,693],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100616841","digital-care-for-holistic-health-in-older-adults-with-diabetes-and-multimorbidity-100616841",false,"NCT07310849","Digital Care for Holistic Health in Older Adults With Diabetes and Multimorbidity","Digital Care Community Common Good Program Enhances Holistic Health Management for Middle Aged and Older Adults With Diabetes Mellitus and Multiple Chronic Conditions","Inclusion Criteria:\n\n* Age and Consent: Individuals aged 50 years or older who are willing to provide written informed consent.\n* Language and Literacy: Participants must be literate and able to communicate in Mandarin or Taiwanese.\n* Medical Diagnosis: Participants must have a physician-confirmed diagnosis of type 2 diabetes mellitus (T2DM) and at least one comorbid chronic disease (e.g., hypertension, hyperlipidemia, chronic kidney disease, or heart disease).\n* Technology Use: Participants must own a smartphone and be willing to use the LINE messaging app and web-based health education links.\n* Residence: Participants must reside within one of the four participating communities and have no plans to move away during the study intervention period.\n\nExclusion Criteria:\n\n* Those with severe diabetes-related complications, such as renal failure, cerebrovascular disease, diabetic foot, or retinopathy.\n* Individuals with psychiatric disorders, undergoing active cancer treatment, or those unable to perform independent self-care (e.g., due to visual impairment or mobility limitations).\n* Individuals without diabetes but with other chronic diseases.\n* Individuals residing in long-term care institutions.\n* Individuals who are simultaneously participating in other intervention programs.","ALL","50 Years",{"count":20,"type":21},169,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study was to explore the effectiveness of the \"Digital Care Community Common Good\" program in improving disease control indicators, self-management abilities, depression, and quality of life among patients with comorbidities and type 2 diabetes. The study was designed as a two-year experimental study, with a specific area in New Taipei City selected as the research site. In the first year, the main tasks include establishing an integrated intervention team composed of primary healthcare providers and community resources, expanding the functionalities of the mHealth platform, developing digital educational materials for diabetes comorbidities care, and recruiting and training 6 to 8 community care volunteers. Additionally, 169 eligible participants with type 2 diabetes and comorbidities will be recruited from four communities, completing baseline assessments and randomization into groups. In the second year, a 6-month intervention and effectiveness evaluation of the \" Digital Care Community Common Good \" program will be implemented. The intervention includes online and in-person educational sessions, telephone care, use of the mHealth platform (featuring educational, data monitoring, contextual learning, interactive, and reminders), as well as home visits, case discussions, and individualized care plans for high-risk cases. Disease control indicators, selfmanagement abilities, depression, and quality of life will be tracked immediately post-intervention, at 3 month, and at 6 month to assess outcomes and changes over time. This study expects to enhance health management for diabetes patients with comorbidities through digital care and interdisciplinary collaboration, offering evidence-based insights and recommendations for policy implementation in the integration of community and primary healthcare models.",[27,28,29,30,31,32],"Type2Diabetes","Hypertension","Dyslipidemia","CKD","Cardio Vascular Disease","Gout Arthritis",[34,35,36,37,38],"community care","diabetes mellitus","multimorbidity","quality of life","self-management","RECRUITING","2026-08-20",{"date":42,"type":43},"2026-08-21","ACTUAL",{"date":45,"type":43},"2026-05-12",{"date":47,"type":21},"2027-07-01",{"name":49,"class":50},"Chang Gung University of Science and Technology","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100652757","phase-1-a-study-to-assess-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-hs-10582-in-healthy-subjects-and-subjects-with-mildly-elevated-ldl-c-levels-100652757","NCT07777003","A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10582 in Healthy Subjects and Subjects With Mildly Elevated LDL-C Levels","A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10582 Tablets After Single and Multiple Oral Doses in Healthy Subjects and Subjects With Mildly Elevated LDL-C","Inclusion Criteria:\n\n* For all participants\n* Participants have a full understanding of the study content, process, and possible adverse reactions, are willing to complete the study in strict accordance with the study protocol, and voluntarily sign the ICF;\n* Participants must be 18 to 55 years of age (inclusive) at the time of signing the ICF;\n* Body mass index (BMI) between 19.0 and 32.0 kg\u002Fm2 (inclusive), with body weight not less than 50.0 kg for males and not less than 45.0 kg for females;\n\nExclusion Criteria:\n\n* Participants with clinically significant abnormal vital signs, physical examination, or laboratory results as judged by the investigator during the screening period;\n* Pregnant or lactating women;\n* Any medication taken within 2 weeks or 5 half-lives (whichever is longer) before screening and any medication expected to be taken throughout the study, including prescription drugs, over-the-counter drugs, Chinese herbal medicine, and health products (except for medications used to treat AEs);\n* Participants with concomitant diseases that may significantly affect the absorption of drugs or nutrients as judged by the investigator, such as clinically significant gastrointestinal diseases (e.g., active inflammatory bowel disease) and symptoms of gastrointestinal disorders; or any condition that may affect the absorption of drugs, such as partial or total gastrectomy, gastric bypass, and resection of any intestinal area;\n* Those who should not be enrolled per the investigator's opinion.\n* History of severe allergic\u002Fhypersensitivity reactions or persistent clinically significant allergic\u002Fhypersensitivity reactions, or history of hypersensitivity reactions to drugs with a chemical structure similar to HS-10582 as judged by the investigator;\n* Have participated in clinical studies of any drug or medical device and received at least one treatment (including placebo) within 12 weeks before screening, or are still within 5 half-lives of the investigational drug (whichever is longer, except for those who have not received the investigational drug or device);",true,"18 Years","55 Years",{"count":63,"type":21},76,[65],"PHASE1","This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HS-10582 following single and multiple dose administration to healthy subjects and subjects with Mildly Elevated LDL-C.\n\nThis study will consist of two parts: single ascending dose (SAD) and multiple ascending dose (MAD).",[29],[69],"Elevated LDL-C；Hypercholesterolemia","NOT_YET_RECRUITING","2026-08-17",{"date":40,"type":43},{"date":74,"type":21},"2026-09-30",{"date":76,"type":21},"2027-12-31",{"name":78,"class":79},"Jiangsu Hansoh Pharmaceutical Co., Ltd.","INDUSTRY",{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100611282","a-novel-digital-tool-physicians-can-use-to-prescribe-exercise-to-patients-with-cardiovascular-disease-risk-factors-100611282","NCT07238556","A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors","Feasibility and Acceptability of a Novel Algorithm for Physicians to Prescribe Personalized Exercise Prescriptions to Patients With Cardiovascular Disease Risk Factors: Study Protocol for an Exploratory Randomized Controlled Crossover Trial","P3-EX","Physician Inclusion Criteria\n\n1. Practicing medical doctors employed at the study recruitment sites\n2. Do not recommend written exercise programs or plans to their patients, nor refer them to exercise clinics or exercise professionals\n3. Are willing to recruit two of their patients to deliver Prioritize Personalize Prescribe EXercise (P3-EX) and American College of Sports Medicine Physical Activity Vital Sign (ACSM PAVS)\n\nPatient Inclusion Criteria\n\n1. Sedentary: have not performed planned, structured physical activity at moderate intensity for ≥30 minutes on ≥3 days per week in the last 3 months\n2. Adults: ≥18 and ≤64 yrs\n3. ≥1 cardiovascular disease risk factors: Having obesity, hypertension, dyslipidemia, and\u002For diabetes (or prediabetes)\n\n   * Obesity: BMI ≥30 kg\u002Fm2 or WC \\>102 cm (40 in) for men and \\>88 cm (35 in) for women\n   * Hypertension: Systolic BP ≥130 mm Hg and\u002For diastolic BP ≥80 mm Hg, or on antihypertensive medication\n   * Dyslipidemia: LDL-C ≥130 mg\u002FdL (3.37 mmol\u002FL), or HDL-C \\\u003C40 mg\u002FdL (1.04 mmol\u002FL) in men and \\\u003C50 mg\u002FdL (1.3 mmol\u002FL) in women, or non-HDL-C ≥160 mg\u002FdL (4.14 mmol\u002FL), or on lipid-lowering medication, or TC ≥200 mg\u002FdL (5.18 mmol\u002FL)\n   * Diabetes (or prediabetes): FBG ≥100 mg\u002FdL or HbA1c ≥5.7%, or on medication for diabetes\n4. Healthy: Having no signs or symptoms of or have cardiovascular or renal disease, or other diseases or health conditions that significantly limit physical activity engagement\n5. Not pregnant or lactating\n6. Not a cigarette smoker or quit smoking ≥6 months ago\n7. Consume \\\u003C2 alcoholic drinks daily\n8. Able to use a computer or phone with internet access\n9. Fluent in English\n10. Willing to maintain their medication routine and habitual diet and not follow other exercise or nutrition programs.\n\nPatient Exclusion Criteria 4a. Have pain or discomfort in the chest, neck, jaw, or arms; dizziness or syncope; shortness of breath at rest or with mild exertion; unusual fatigue or shortness of breath with usual activities; orthopnea; ankle edema; intermittent claudication; palpitations; or known heart murmur 4b. Stroke or cancer survivors or currently have cancer, chronic obstructive pulmonary disease, musculoskeletal injury, chronic back pain, depression, dementia, or other diseases or health conditions that are deemed to significantly limit physical activity engagement.","64 Years",{"count":90,"type":21},72,[24],"The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA. Physicians will recruit two patients each (N=48) having CVD risk factors. Physicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Physicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for physicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for physicians to use to prescribe customized exercise routines for patients with CVD risk factors, and physicians and patients will be satisfied with P3-EX.",[28,29,94,95,96],"Diabetes Mellitus","Obesity","Cardiovascular Disease",[98,99,100,101,102,103,104,105,106],"Exercise prescription","Exercise Therapy","Physical Activity","Preventive Health Services","Health Behavior","Medical Informatics Applications","Health technology","Precision Medicine","Primary Health Care","2026-08-11",{"date":109,"type":43},"2026-08-12",{"date":111,"type":43},"2026-03-30",{"date":113,"type":21},"2026-12-31",{"name":115,"class":50},"University of Connecticut",3,{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":59,"sex":17,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":51},"100645991","cardiometabolic-effects-of-the-recommended-daily-pecan-intake-dose-100645991","NCT07696403","Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose","Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose: A 12-Week Randomized Controlled Trial","Inclusion Criteria:\n\n* 25-75 year-old men and women at increased risk for cardiovascular disease. Increased risk for cardiovascular disease will be defined by either elevated cholesterol profiles -or- overweight\u002Fobesity.\n* Elevated cholesterol profiles will be defined as:\n* \"Borderline High\" and\u002For \"at risk\" in two or more of the following variables (total cholesterol: 180-239 mg\u002FdL, LDL cholesterol 110-159 mg\u002FdL, triglycerides 130-199 mg\u002FdL) --or-- \"High\" in total cholesterol (240 mg\u002FdL and higher), LDL (160 mg\u002FdL or higher), or triglycerides (between 200-350 mg\u002FdL).\n* Overweight\u002Fobesity will be defined by body mass index (overweight \\> 28 kg\u002Fm2 or obesity 30 kg\u002Fm2 or greater).\n\nExclusion Criteria:\n\n* Probable familial hypercholesterolemia, defined by: total cholesterol greater than 290 mg\u002FdL or LDL levels greater than 190 mg\u002FdL plus a family history of myocardial infarction (MI) before 50 years of age in a 2nd-degree relative or below age 60 in a 1st-degree relative.\n* Women on hormone replacement therapy less than 2 years.\n* Women who are pregnant or nursing\n* Individuals who regularly exercise more than 3h\u002Fw\n* Weight gain or loss of more than 5% body weight in the past 3 months\n* Plans to begin a weight loss\u002Fexercise regimen during the trial\n* History of medical or surgical events that could affect digestion or swallowing\n* Gastrointestinal surgeries, conditions, or disorders\n* Any chronic diseases (including moderate to severe asthma, chronic lung disease, and kidney disease)\n* Metabolic disease\n* Atherosclerosis\n* Previous MI or stroke\n* Cancer\n* Fasting blood glucose levels greater than 126 mg\u002FdL\n* Blood pressure greater than 180\u002F120 mmHg\n* Medication use affecting digestion, absorption, or metabolism (e.g. thyroid meds), lipid-lowering medications, medications for diabetes, steroid\u002Fhormone therapies, or current antibiotic cycles\n* Medically prescribed or special diets\n* Food allergies (specific to the foods in the study, including tree nuts, dairy, gluten, palm oil, and coconut oil)\n* Fish oil supplements\n* Individuals who regularly consume nuts and\u002For nut butter (defined as consumption of \\>2 servings (\\~56g) of tree nuts, nuts, or nut butter (e.g., peanut butter, almond butter) per week\n* Excessive alcohol use (greater than 3 drinks\u002Fday for men; greater than 2 drinks\u002Fday for women)\n* Tobacco or nicotine use\n* Underweight BMI (\\\u003C18.5 kg\u002Fm²)\n* Individuals who have donated blood or plasma in the past 2 weeks\n* Anemia or hemoglobin levels \\\u003C13.0 g\u002FdL (men) or \\\u003C12.5 (women)","25 Years","75 Years",{"count":127,"type":21},90,[24],"Cardiovascular disease risk factors, including higher BMIs and poor cholesterol profiles, are on the rise and contribute to the United States' growing disease burden. The bioactive compounds contained in tree nuts have been shown to beneficially affect cardiometabolic health outcomes. Pecans contain more total phenols, sterols, and flavonoids than any other tree nut. They also are a rich source of polyunsaturated fatty acids (PUFAs), fiber, vitamin A, vitamin E, folic acid, calcium, magnesium, phosphorus, potassium, and zinc. These bioactive components in pecans are likely the reason for the previously documented improvements in cardiometabolic health. This study aims to examine the impact of a low dose of pecans on changes in fasting and postprandial lipid metabolism\u002Fblood lipids and markers of chronic disease risk.\n\nThe specific aims of this study are to:\n\n* Examine the effect of pecan consumption at a dose of 6% of total energy needs for 12 weeks on fasting and postprandial blood lipids.\n* Examine the effect of pecan consumption at a dose of 6% of total energy needs for 12 weeks on other markers of chronic disease risk.\n\nParticipants will be asked to:\n\n* Consume pecans daily for 12 weeks or maintain their current habitual diet.\n* Attend two short visits at 4 and 8 weeks for fasting blood draws, body measurements, and to collect their next 4 weeks' supply of study materials.\n* Attend two longer (5 h) testing visits, which include eating a standard breakfast meal and having their blood drawn periodically before and after breakfast.\n\nResearchers will compare the Pecan and Control groups to examine the physiologic effects of incorporating a low dose of pecans into one's diet.",[131,29,132],"Nutrition, Healthy","Overweight and Obesity","2026-08-06",{"date":107,"type":43},{"date":136,"type":21},"2027-03",{"date":138,"type":21},"2030-02",{"name":140,"class":50},"University of Georgia",{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":152,"conditions":153,"keywords":156,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":4},"100649008","vitamin-d-status-and-lipid-profile-in-obese-adults-with-type-2-diabetes-100649008","NCT07729553","Vitamin D Status and Lipid Profile in Obese Adults With Type 2 Diabetes","Association Between Serum 25-Hydroxyvitamin D Status and Lipid Profile Among Obese Adults With Type 2 Diabetes Mellitus: A Cross-Sectional Study","VILD-T2D","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Established diagnosis of type 2 diabetes mellitus (T2DM) according to standard diagnostic criteria.\n* Obesity based on body mass index (BMI) criteria.\n* Availability of serum 25-hydroxyvitamin D \\[25(OH)D\\] measurement.\n* Availability of lipid profile and glycemic laboratory parameters.\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus.\n* Pregnancy.\n* Known chronic kidney disease.\n* Chronic liver disease.\n* Active malignancy.\n* Acute infection or inflammatory disease.\n* Conditions affecting gastrointestinal absorption.\n* Use of medications or supplements that substantially alter vitamin D metabolism (when applicable).",{"count":150,"type":21},150,"OBSERVATIONAL","This prospective, single-center, cross-sectional observational study aims to evaluate the association between serum 25-hydroxyvitamin D concentrations and lipid profile parameters among adults with obesity and established type 2 diabetes mellitus. A total of 160 participants will be recruited from an outpatient diabetes clinic in Cairo, Egypt. Each participant will undergo a single clinical, anthropometric, and laboratory assessment. No intervention or treatment will be assigned by the investigators.",[154,95,29,155],"Type 2 Diabetes Mellitus","Vitamin D Deficiency",[154,157,158],"Obesity; Vitamin D Deficiency; Dyslipidemia; Lipid Metabolism","Cardiometabolic Risk","2026-07-22",{"date":161,"type":43},"2026-07-27",{"date":163,"type":21},"2026-07-25",{"date":165,"type":21},"2027-02-28",{"name":167,"class":50},"Sinai University",{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":59,"sex":17,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":184,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":199},"100647756","effect-of-macaba-oil-combined-with-green-exercises-100647756","NCT07715461","Effect of macaúba Oil Combined With Green Exercises","Macaúba Oil and Green Exercises: Impacts on Lipid Oxidation and Mental Stress in Trained Individuals","Inclusion Criteria:\n\n* Aged 35 to 59 years\n* Body mass index (BMI) below 30 m\u002Fkg²\n* Body fat below 25%, with stability of body mass in the last six months\n* Being physically active (performing moderate physical activity or \\\u003C75 min \u002F being vigorous physical activity)\n* Being apparently healthy according to the Physical Activity Readiness Questionnaire.\n\nExclusion Criteria:\n\n* Musculoskeletal injury that limits the ability to exercise at moderate intensity during the study period\n* Use of supplements, anti-inflammatory drugs and\u002For analgesics during the study period\n* Use of any therapy for muscle pain during the study period.","35 Years","59 Years",{"count":178,"type":21},60,[24],"Animal model studies involving macaúba oil demonstrate beneficial effects on fat, oxidative stress, and adipogenesis. This study aims to evaluate lipid oxidation and mental stress levels in trained individuals following macaúba oil supplementation combined with outdoor exercise (green exercise) performed in a fasted state. The study will be randomized, double-blind, and placebo-controlled. Participants will receive either 400 mg of macaúba oil or placebo pills over an 8-week period while engaging in 5 km running sessions four times a week. Assessments of anthropometric parameters, body composition (DEXA), biochemical parameters, and heart rate will be conducted before and after the intervention, alongside the administration of a questionnaire regarding emotional well-being and perceived stress. At the end of the intervention, results will be analyzed using Kubios HRV 2.0 and GraphPad Prism (version 5.0) software; the Kolmogorov-Smirnov and Shapiro-Wilk tests will be applied to verify data normality, the Student's t-test for parametric data, and the Kruskal-Wallis and Wilcoxon-Mann-Whitney tests for non-parametric data.",[182,29,183],"Stress Mental","Obesity & Overweight",[185,186,187,188,189],"Mitochondria","Lipid oxidation","Macauba oil","Fasting","Green exercises","2026-07-16",{"date":192,"type":43},"2026-07-20",{"date":194,"type":21},"2026-08-01",{"date":196,"type":21},"2027-01-30",{"name":198,"class":50},"Federal University of Minas Gerais",2,{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":17,"minAge":124,"maxAge":176,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":216,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":51},"100647585","effects-of-policosanol-and-exercise-on-fitness-and-lipids-in-people-with-elevated-blood-lipids-100647585","NCT07710261","Effects of Policosanol and Exercise on Fitness and Lipids in People With Elevated Blood Lipids","Effect of Policosanol Supplementation Combined With Concurrent Exercise Training on Physical Fitness and Lipid Profiles in Healthy Volunteers With Elevated Blood Lipid But Not Required Medical Treatment","Inclusion Criteria:\n\n* Men and women aged 25 to 59 years.\n* BMI between 18.5 and 29.9 kg\u002Fm².\n* Diagnosed with or presenting with dyslipidemia within the past 3 months, based on laboratory assessment at baseline or a standard laboratory report issued within the past 3 months, according to the National Cholesterol Education Program Adult Treatment Panel III criteria, defined by at least one of the following:\n* Total cholesterol ≥ 200 mg\u002FdL;\n* Low-density lipoprotein cholesterol ≥ 130 mg\u002FdL and \\\u003C 190 mg\u002FdL;\n* High-density lipoprotein cholesterol \\\u003C 40 mg\u002FdL in men;\n* High-density lipoprotein cholesterol \\\u003C 50 mg\u002FdL in women;\n* Triglycerides ≥ 150 mg\u002FdL.\n* Free from chronic or comorbid conditions that contraindicate participation in aerobic or resistance exercise.\n* Cleared for physical activity based on the Physical Activity Readiness Questionnaire for Everyone.\n* Not regularly physically active during the preceding 3 months, defined as fewer than 3 exercise sessions per week or less than 150 minutes of exercise per week.\n* Able and willing to participate in the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Current or recent use within the past 3 months of lipid-lowering medications or dietary supplements known to influence lipid metabolism, including statins, fibrates, niacin, omega-3 fatty acids, red yeast rice, or policosanol.\n* Known allergy or hypersensitivity to policosanol, sugarcane derivatives, capsule components, or any excipients in the supplement formulation.\n* Presence of chronic or comorbid conditions that may make exercise participation unsafe, including but not limited to cardiovascular disease, chronic obstructive pulmonary disease, severe arthritis, osteoporosis, uncontrolled diabetes, gastrointestinal disorders, or neurological impairments affecting movement control.\n* High-risk lifestyle factors, including heavy smoking, excessive alcohol consumption, or use of recreational drugs.\n\nInability to comply with the study protocol, including inability to participate in the exercise program when assigned or inability to attend scheduled follow-up assessments.\n\n\\- Refusal or inability to provide written informed consent independently.",{"count":208,"type":21},120,[24],"This study will evaluate the effects of policosanol supplementation, concurrent exercise training, and their combination on physical fitness, muscle recovery, inflammatory markers, and blood lipid profiles in adults with elevated blood lipids who are not currently indicated for lipid-lowering medication.\n\nParticipants will be randomly assigned to one of four groups for 12 weeks: policosanol plus exercise training, policosanol alone, placebo plus exercise training, or placebo without structured exercise training. Participants assigned to the supplementation groups will take policosanol 5 mg per day, while those assigned to the placebo groups will take a matching placebo. Participants assigned to the exercise groups will complete a standardized concurrent exercise training program combining aerobic and resistance exercise.\n\nThe study will compare changes in physical fitness, lipid profiles, and selected blood biomarkers before and after the intervention. The findings may help determine whether low-dose policosanol, alone or combined with exercise training, can support cardiometabolic health and physical fitness in adults with dyslipidemia.",[29,212,213,214,215],"Elevated Blood Lipids","Physical Fitness","Exercise Training","Muscle Function, Handgrip Strength Test",[217,218,219,220,221,222,223,224,213,29,225],"Policosanol","Octacosanol","Dietary Supplement","Concurrent Exercise Training","Aerobic Exercise","Resistance Exercise","Blood Lipid Profile","Muscle Function","Nutraceutical","2026-07-15",{"date":228,"type":43},"2026-07-17",{"date":230,"type":21},"2026-06-22",{"date":232,"type":21},"2027-01-29",{"name":234,"class":50},"Mahidol University",{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":17,"minAge":243,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":22,"phases":247,"briefSummary":248,"conditions":249,"keywords":253,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":51},"100645658","kodo-millet-porridge-and-its-effects-on-gut-health-and-metabolic-syndrome-100645658","NCT07703371","Kodo Millet Porridge and Its Effects on Gut Health and Metabolic Syndrome","Impact of Dietary Fiber-Rich Kodo Millet Porridge Supplementation on Gut Microbiome and Metabolic Syndrome","KMGMS","Inclusion Criteria\n\n* Adults aged 20-60 years.\n* Willingness to provide informed consent.\n* Willingness to consume Kodo millet porridge daily for 12 weeks.\n* No planned changes in diet or physical activity during the study.\n* Overweight or obese (BMI ≥ 25 kg\u002Fm²), placing them at risk for metabolic disorders.\n\nExclusion Criteria\n\n* Known allergies to millet or any porridge ingredients.\n* Individuals who are taking on-counter dietary fiber and probiotics supplements\n* History of any chronic gastrointestinal diseases (e.g., IBD, gastritis, irritable bowel syndrome).\n* Pregnant or lactating women.\n* Antibiotic use in last 3 months.\n* Alcohol abuse, more than 2 drink per day\n* Presence and usage of medications for any serious chronic illnesses, including uncontrolled diabetes (HbA1c \\> 9), cardiovascular disease (aldosterone antagonists, alpha blockers, alpha-beta blockers, anticoagulants, antiplatelets, angiotensin-converting enzyme inhibitors, angiotensin 2 receptor blockers, beta blockers, calcium channel blockers, diuretics, digoxin) , renal disease, neurological or mental disorders, coagulation disorders, and cancer.","20 Years","60 Years",{"count":246,"type":21},50,[24],"Dietary fiber are components in foods that are not digested by human gastrointestinal enzymes (alpha amylase and alpha glucosidase) but are instead broken down and fermented by gut microbes. The byproducts generated during fermentation in the large intestine, primarily short-chain fatty acids (SCFA), bile acids, indoles, and their derivatives, circulate through the circulatory system to the liver, lungs, brain, adipose tissue, and muscles, where they modulate metabolism (suppress lipogenesis and alleviate insulin resistance) and immune function. Individuals who are overweight or obese frequently exhibit gut dysbiosis, characterized by lower SCFA producing commensals. This condition predisposes them to metabolic disorders such as insulin resistance, dyslipidemia, and hypertension, and contributes to conditions including type 2 diabetes, cardiovascular disease, and metabolic dysfunction-associated steatotic liver disease. Preclinical and clinical research have demonstrated that the consumption of fiber-rich foods maintains or restores gut microbiota health and diminishes the risk of metabolic disorders. Kodo millet (Paspalum scrobiculatum), a small millet, is rich in dietary fiber and we have developed a palatable kodo millet porridge beverage enriched with polyphenols and dietary fiber. The purpose of this study is to examine the effects of consuming Kodo millet porridge beverage as a nutritional supplement for 3 months, on gut microbiome richness (composition and diversity) and metabolic health in overweight or obese people.",[183,250,251,252,29],"Metabolic Syndrome","Gut Dysbiosis","Insulin Resistance",[254,255,256,257,258,250,95,251,29,259,260,261,262,263,264],"Kodo Millet","Dietary Fiber","Gut Microbiome","Short-Chain Fatty Acids","16S rRNA Sequencing","Glycemia","Prebiotic","Small Millet","Porridge","Antioxidant","Inflammation","2026-07-11",{"date":267,"type":43},"2026-07-14",{"date":269,"type":43},"2026-06-01",{"date":271,"type":21},"2026-11-16",{"name":273,"class":50},"JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RESEARCH",{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":22,"phases":284,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":300},"100591438","phase-1-a-study-to-investigate-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-azd4954-in-healthy-adult-participants-with-or-without-elevated-lipoprotein-a-lpa-levels-and-participants-with-dyslipidemia-100591438","NCT06980428","A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia","A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4954 Following Single and Multiple Ascending Dose Administration to Healthy Participants With or Without Elevated Lp(a) Levels, and Participants With Dyslipidemia","Inclusion Criteria:\n\nAll Parts:\n\n* Participants with plasminogen level (concentration) within normal range at the Screening Visit.\n* All females must have a negative pregnancy test at the Screening Visit and on admission to the study site.\n* Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception.\n* Females of non-childbearing potential must be confirmed at the Screening Visit.\n* Sexually active fertile male participants with partners of childbearing potential must adhere to the study specific contraception methods from the time of first administration of study intervention until 3 months after the study Follow-up Visit.\n\nParts A and B (Healthy Participants):\n\n* Male and female participants aged 18 to 65 years with suitable veins for cannulation or repeated venipuncture.\n* Have a body mass index (BMI) between 18 and 35 kg\u002Fm² inclusive.\n* For Japanese and Chinese participants (Parts A and B):\n\n  1. A Japanese participant is defined as having both parents and 4 grandparents who are ethnically Japanese. This includes second and third generation Japanese whose parents or grandparents are living in a country other than Japan.\n  2. A Chinese participant is defined as having both parents and 4 grandparents who are ethnically Chinese. This includes second and third generation Chinese whose parents or grandparents are living in a country other than China.\n\n     Part B (Healthy Participants):\n* Participants must have elevated Lp(a) ≥ 30 mg\u002FdL at the Screening Visit.\n\nPart B (Participants with Dyslipidemia):\n\n* Male and female participants aged 18 to 70 years with suitable veins for cannulation or repeated venipuncture.\n* Have a BMI \\> 18 kg\u002Fm².\n* Participants must have elevated Lp(a) ≥ 70 mg\u002FdL at the Screening Visit.\n* Participants with a fasting LDL-C ≥ 70 mg\u002FdL and \\\u003C 190 mg\u002FL at the Screening Visit.\n* Participants should be receiving moderate or high-intensity statin therapy for ≥ 2 months prior to the Screening Visit, according to the American College of Cardiology\u002FAmerican Heart Association guidelines on blood cholesterol management.\n* Participants with documented coronary artery disease, stroke, or peripheral artery disease or at moderate or high risk for an atherosclerotic cardiovascular disease event.\n* There should be no planned medication or dose change during study participation.\n\nExclusion Criteria:\n\nAll Parts:\n\n* History of any clinically important disease or disorder.\n* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* Any clinically important illness, medical\u002Fsurgical procedure, or trauma within 4 weeks of the first administration of study intervention.\n* Participants with known bleeding or coagulation disorders.\n* Participants who have an elevated high-sensitivity C-reactive protein (\\> 3 mg\u002FL) or have a prothrombin time\u002Finternational normalized ratio (PT\u002FINR) or activated partial thromboplastin time (aPTT) \\> 1.25 times × upper limit normal (ULN).\n* Any clinically important abnormalities in hematology, coagulation, clinical chemistry, urinalysis, abnormal vital signs or abnormal laboratory values.\n* Any positive result on Screening for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus (HCV) or human immunodeficiency virus (HIV).\n* Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead electrocardiogram (ECG) at Screening.\n* Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of study intervention.\n\nParts A and B (Healthy Participants):\n\n* Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol\u002Facetaminophen), herbal remedies, intake of \\> 3 × daily recommended levels of vitamins and minerals during the 2 weeks prior to the first administration of study intervention or longer if the medication has a long half-life.\n* Current smokers or those who have smoked or used nicotine products.\n\nPart B (Participants with Dyslipidemia):\n\n* Acute ischemic cardiovascular event in the last 12 months prior to randomization.\n* Poorly controlled diabetes.\n* Previous administration of Lp(a) inhibitor.\n* Have uncontrolled hypertension.\n* Abnormal vital heart rate.","70 Years",{"count":283,"type":21},136,[65],"The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4954 in healthy participants with or without elevated Lipoprotein(a) (Lp\\[a\\]) levels and participants with dyslipidemia.",[287,29],"Healthy Participants",[289,290],"Lipoprotein(a)","Low-density lipoprotein cholesterol (LDL-C)","2026-07-10",{"date":293,"type":43},"2026-07-13",{"date":295,"type":43},"2025-05-27",{"date":297,"type":21},"2026-12-04",{"name":299,"class":79},"AstraZeneca",6,{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":309,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":312,"conditions":313,"keywords":316,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":51},"100646296","taiwan-green-propolis-for-blood-lipids-and-body-fat-in-patients-with-masld-100646296","NCT07692438","Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD","A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Effectiveness of Taiwan Green Propolis Supplementation on Blood Lipids and Body Fat in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","TGP-MASLD","Inclusion Criteria:\n\n* Adults aged 18 to 80 years\n* Diagnosis of hepatic steatosis (fatty liver) confirmed by abdominal ultrasound, PLUS at least one of the following metabolic risk factors:\n\n  1. Overweight or obesity: BMI \\>= 23 kg\u002Fm\\^2\n  2. Elevated waist circumference: \\>= 90 cm in men or \\>= 80 cm in women (South Asian and Chinese criteria)\n  3. Dysglycemia or type 2 diabetes: prediabetes (HbA1c 5.7-6.4%, or fasting glucose 100-125 mg\u002FdL, or OGTT 2-hour glucose 140-199 mg\u002FdL) OR type 2 diabetes (HbA1c \\>= 6.5%, or fasting glucose \\>= 126 mg\u002FdL, or OGTT 2-hour glucose \\>= 200 mg\u002FdL, or current pharmacological treatment for type 2 diabetes)\n  4. Elevated triglycerides: \\>= 150 mg\u002FdL or currently on lipid-lowering therapy\n  5. Low HDL-C: \\\u003C= 39 mg\u002FdL in men or \\\u003C= 50 mg\u002FdL in women, or currently on lipid-lowering therapy\n  6. Elevated blood pressure: \\>= 130\u002F85 mmHg or currently on antihypertensive treatment\n\nExclusion Criteria:\n\n* Known allergy to honey, propolis, multiple pollens, or alcohol\n* Psychiatric disorder or cognitive impairment\n* Currently pregnant or breastfeeding\n* Significant endocrine abnormality, or major disease of the heart, liver (other than MASLD), or kidney\n* Difficulty swallowing capsules\n* Dementia, impaired consciousness, or inability to respond to questionnaires","80 Years",{"count":178,"type":21},[24],"Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver condition linked to excess body fat, high blood lipids, and other metabolic problems. Taiwan green propolis is a natural health product collected by bees from plants, which has shown potential benefits for blood lipids and body fat in laboratory and animal studies. However, its effects in people with MASLD have not been well established in clinical trials.\n\nThis study is a double-blind, randomized, placebo-controlled trial enrolling up to 60 adults with MASLD at Dalin Tzu Chi Hospital in Taiwan. Eligible participants are randomly assigned in a 1:1 ratio to receive either Taiwan green propolis capsules or matching placebo capsules for 12 weeks. Participants take 2 capsules before breakfast and 2 capsules before dinner each day (4 capsules per day total). Neither participants nor the research team know which capsules are being taken until the study ends.\n\nThe study measures changes in blood lipids (triglycerides, total cholesterol, LDL-C, and HDL-C), body fat percentage, body weight, waist circumference, liver enzymes, blood sugar levels, inflammatory markers, and health-related quality of life. Liver fat and scarring are assessed by abdominal ultrasound before and after the intervention. Gut microbiota samples are also collected. Assessments are conducted at baseline, at 4 weeks, 8 weeks, 12 weeks (end of intervention), and at follow-up visits 2 weeks and 12 weeks after the intervention ends.\n\nThe goal of this study is to provide scientific evidence on whether Taiwan green propolis can safely and effectively improve blood lipids, body fat, and metabolic health in people with MASLD, and to explore the relationship between physiological improvements and health behavior changes.",[314,315,29,183],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Non-alcoholic Fatty Liver Disease NAFLD",[317,318,319,320,321,322,323],"green propolis","propolis","dietary supplement","MASLD","fatty liver","blood lipids","randomized controlled trial","2026-07-02",{"date":326,"type":43},"2026-07-09",{"date":328,"type":43},"2025-05-28",{"date":330,"type":21},"2028-09-30",{"name":332,"class":50},"Taipei Medical University",{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":22,"phases":342,"briefSummary":343,"conditions":344,"keywords":348,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":4},"100646963","electronic-health-record-augmented-ldl-cholesterol-optimization-and-control-via-active-lipid-engagement-ehr-locale-a-quality-improvement-implementation-study-100646963","NCT07685639","Electronic Health Record Augmented LDL-Cholesterol Optimization and Control Via Active Lipid Engagement (EHR-LOCALE): A Quality Improvement Implementation Study","EHR-LOCALE","Inclusion Criteria:\n\n1. Adults over the age of 18\n2. Resident of Alberta\n3. Individuals hospitalized with an acute coronary syndrome and have undergone coronary angiography.\n4. Able to participate in follow-up contact if randomized to the intervention arm\n\nExclusion Criteria:\n\n1\\. In-hospital mortality",{"count":341,"type":21},2000,[24],"The purpose of this study is to determine whether a proactive, EHR-guided approach helps more individuals reach safe cholesterol levels, improves medication use, and reduces future heart attacks and strokes, compared to usual care.\n\nThe main question it aims to answer is:\n\n• Does the EHR-LOCALE pathway increases the proportion of patients who reach the LDL-cholesterol target of \\\u003C1.8 mmol\u002FL at 6 months?\n\nParticipants in the interventional group receive:\n\n* Pharmacist contact\n* Repeat lipid requisitions\n* Review of medications, adherence, and side effects\n* Treatment escalation according to national dyslipidemia guidelines",[345,346,29,347],"ACS (Acute Coronary Syndrome)","Hyperlipidemia","Low-Density-Lipoprotein-cholesterol Level",[29,349,350,351,352,353],"Canadian VIGOUR Centre","LDL","ACS","triglycerides","lipid","2026-06-29",{"date":356,"type":43},"2026-07-06",{"date":358,"type":21},"2026-08",{"date":360,"type":21},"2027-09",{"name":362,"class":50},"University of Alberta",{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":59,"sex":17,"minAge":369,"maxAge":370,"enrollmentInfo":371,"targetDuration":4,"studyType":22,"phases":373,"briefSummary":367,"conditions":374,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":51},"100646839","phase-1-a-randomized-open-label-two-arm-two-period-multiple-dose-study-to-evaluate-pharmacokinetic-drug-drug-interaction-safety-and-tolerability-of-uic202601-and-uic202602-in-healthy-volunteers-100646839","NCT07682948","A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers","Inclusion Criteria:\n\n* Subjects aged 19 years or older and less than 55 years at the screening visit.\n* Subjects with a body weight of at least 50 kg (at least 45 kg for females) and a body mass index (BMI) of 18.0 kg\u002Fm² or higher and 30.0 kg\u002Fm² or lower at the screening visit.\n\nBMI (kg\u002Fm²) = Body weight (kg) \u002F Height (m)²\n\n* Subjects who have no clinically significant congenital or chronic diseases and no pathological symptoms or findings based on medical examination at the screening visit.\n* Subjects determined to be eligible for participation in the clinical trial by the Investigator (or delegated Sub-investigator) based on the evaluation results of hematology, blood chemistry, serology, urinalysis, other clinical laboratory tests, physical examination, and electrocardiogram (ECG), which are established and performed according to the characteristics of the investigational product.\n* Subjects who agree that they and\u002For their spouse or partner will use highly effective contraception (excluding hormonal contraceptives) from the first administration of the investigational product until 14 days after the last administration to prevent pregnancy and who agree not to donate sperm or ova.\n\n  * Highly effective methods of contraception: intrauterine device (IUD), bilateral tubal occlusion, vasectomized partner, sexual abstinence.\n* Subjects who have received and understood sufficient explanation regarding the purpose, procedures, characteristics of the investigational product, and anticipated adverse events of this clinical trial, and who have voluntarily signed the informed consent form.\n\nExclusion Criteria:\n\n* Subjects with current or past history of clinically significant diseases involving the renal system (e.g., severe renal impairment), nervous system (e.g., cerebrovascular disease), immune system, respiratory system (e.g., bronchial asthma), urinary system, gastrointestinal system, endocrine system (e.g., congenital lipid metabolism disorders, severe diabetes mellitus), hematologic\u002Foncologic system, cardiovascular system (e.g., severe hypertension, heart failure, coronary artery disease), reproductive system (e.g., endometrial hyperplasia, endometriosis), psychiatric disorders, or myopathy.\n* Subjects with a history of gastrointestinal surgery (except simple appendectomy or hernia repair) that may affect drug absorption, or with gastrointestinal disease.\n* Subjects with severe hepatic impairment, biliary obstruction, or cholestasis (this drug is excreted almost entirely via bile. Cholestasis, biliary obstructive disease, or hepatic impairment may be expected to reduce hepatic clearance.).\n* Subjects with active liver disease or persistent elevation of aminotransferase levels of unknown cause.\n* Subjects with hereditary angioedema or a history of angioedema during treatment with an ACE inhibitor or an angiotensin II receptor blocker.\n* Subjects who have taken enzyme-inducing or enzyme-inhibiting drugs such as barbiturates within 1 month before the first administration, or who have taken medications that may interfere with this clinical trial within 10 days before the first administration (however, participation may be allowed after considering pharmacokinetic and pharmacodynamic characteristics such as interactions with the investigational product and drug half-life).\n* Subjects who have consumed grapefruit-containing foods within 7 days before the first administration or who are unable to refrain from consuming such foods during the clinical trial.\n* Subjects who have participated in another clinical trial or bioequivalence study and received an investigational product within 6 months before the first administration.\n* Subjects who have donated whole blood within 8 weeks before the first administration, donated blood components within 2 weeks, or received a blood transfusion within 4 weeks.\n* Subjects considered unsuitable for participation based on screening assessments performed within 30 days before the first administration of the investigational product.\n\n  * AST or ALT \\> 1.5 × the upper limit of the normal range.\n  * Total bilirubin \\> 1.5 × the upper limit of the normal range.\n  * eGFR (estimated Glomerular Filtration Rate), calculated using the MDRD (Modification of Diet in Renal Disease) equation, \\\u003C 60 mL\u002Fmin\u002F1.73m².\n  * Positive results for serologic tests (hepatitis B, hepatitis C, human immunodeficiency virus \\[HIV\\], or syphilis).\n  * After at least 5 minutes of rest, seated vital signs showing systolic blood pressure \\> 139 mmHg or \\\u003C 100 mmHg, or diastolic blood pressure \\> 90 mmHg or \\\u003C 60 mmHg.\n* Subjects who meet any of the following conditions within 1 month before the first administration.\n\n  * Average alcohol consumption exceeding 21 drinks\u002Fweek for males.\n  * Average alcohol consumption exceeding 14 drinks\u002Fweek for females.\n\n    (1 drink = 50 mL of soju, 30 mL of spirits, or 250 mL of beer.)\n  * Smoking more than 10 cigarettes per day on average.\n* Subjects who meet any of the following conditions.\n\n  * Subjects with hypersensitivity to this drug or any of its components.\n  * Subjects with hereditary problems of fructose or galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.\n* Subjects whom the Investigator (or delegated Sub-investigator) considers unsuitable for participation in this clinical trial for reasons other than the above inclusion\u002Fexclusion criteria (e.g., excessive tattoos).\n* Subjects with a history of drug abuse within 1 year before screening or those with a positive urine drug screening test.\n* Female subjects who are pregnant, suspected to be pregnant, or breastfeeding.","19 Years","54 Years",{"count":372,"type":21},36,[65],[28,29],"2026-06-28",{"date":356,"type":43},{"date":378,"type":21},"2026-07-01",{"date":380,"type":21},"2026-09",{"name":382,"class":79},"Korea United Pharm. Inc.",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":125,"enrollmentInfo":391,"targetDuration":4,"studyType":22,"phases":393,"briefSummary":394,"conditions":395,"keywords":397,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":405,"completionDateStruct":406,"leadSponsor":408,"locationsCount":410},"100645080","polypills-approach-for-multiple-cardiovascular-risk-factors-100645080","NCT07679828","Polypills Approach for Multiple Cardiovascular Risk Factors","Polypills Approach for Multiple Cardiovascular Risk Factors (PACIF) : a Multicentre, Open-label, Randomized Controlled Trial","PACIF","Inclusion Criteria:\n\n* Men or women\n* Age ≥50 years and \\\u003C75 years\n* Hypertension, defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg among participants not currently taking antihypertensive medication, or systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg among participants currently taking any antihypertensive medication\n* Dyslipidemia, defined as LDL-C ≥1.8 mmol\u002FL (70 mg\u002FdL)\n* Type 2 diabetes with HbA1c ≥6.5% and \\\u003C12%\n* Willing to participate and able to sign informed consent\n\nExclusion Criteria:\n\n* Known secondary cause of hypertension\n* Type 1 diabetes\n* Pancreatic insufficiency or diabetes secondary to pancreatitis\n* Triglycerides ≥5.65 mmol\u002FL (500 mg\u002FdL)\n* History of coronary, carotid, or cerebrovascular revascularization within the previous 12 months\n* History of myocardial infarction or stroke within the previous 6 months\n* NYHA class III-IV heart failure at entry or hospitalization for exacerbation of chronic heart failure within the previous 6 months\n* Abnormal kidney function, defined as estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m² or dialysis\n* Abnormal liver function, defined as alanine aminotransferase or aspartate aminotransferase \\>3 times the upper limit of normal\n* Abnormal serum potassium, defined as serum potassium \\>5.5 mmol\u002FL or \\\u003C3.5 mmol\u002FL\n* Contraindication to any of the components of the polypill\n* Currently living with another PACIF participant\n* Pregnancy, currently trying to become pregnant, or of child-bearing potential and not using birth control\n* Clinical diagnosis of dementia or treatment with medications for dementia\n* History of malignancy\n* Life expectancy \\\u003C3 years\n* Currently participating in another intervention study\n* Any factors judged by the clinic team to be likely to limit adherence to interventions",{"count":392,"type":21},8252,[24],"The Polypill Approach for Multiple Cardiovascular Risk Factors (PACIF) trial is a multicenter randomized controlled trial that will test the effectiveness and safety of a fixed-dose combination strategy for integrated management of hypertension, dyslipidemia, and diabetes among adults aged 50 to 75 years in China. The trial will evaluate whether a simplified regimen combining blood pressure-lowering, lipid-lowering, and glucose-lowering therapy improves the 10-year cardiovascular disease risk score at phase 1. Participants will be followed to determine whether the fixed-dose combination strategy reduces major cardiovascular events and cognitive function compared with usual care at phase 2.",[28,29,396],"Diabetes",[28,29,396,398,399,400,401,402],"Polypill","Cardiovascular disease risk","Cardiovascular Diseases","Cognitive function","Randomized controlled trial","2026-06-25",{"date":378,"type":43},{"date":378,"type":21},{"date":407,"type":21},"2030-03-01",{"name":409,"class":50},"China Medical University, China",12,{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":419,"enrollmentInfo":420,"targetDuration":4,"studyType":22,"phases":421,"briefSummary":423,"conditions":424,"keywords":428,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":436,"leadSponsor":437,"locationsCount":51},"100641620","phase-2-reducing-inflammation-to-improve-vascular-and-bone-outcomes-with-low-dose-colchicine-in-ckd-100641620","NCT07654231","Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD","Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD: A Pilot Randomized Open-Label Trial (RESOLVE-CKD Trial)","RESOLVE-CKD","Inclusion Criteria:\n\n* Men and women aged 18-\\\u003C70 years of all race\u002Fethnicity groups\n* CKD stage 3 (estimated glomerular filtration rate (eGFR) \\>30 to 59 ml\u002Fmin\u002F1.73m2)\n* Urine albumin-to-creatinine ratio (uACR) ≥ 200 mg\u002Fg\n* Cardiac artery calcification (CAC) Agatston score ≥30\n* Hypertension, diabetes, dyslipidemia, or established atherosclerotic cardiovascular disease (ASCVD) (coronary artery disease (CAD), ischemic stroke, and peripheral artery disease), defined by self-report, ICD-10 codes, or the use of medications for these conditions.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Current Colchicine therapy\n* Hepatic disease\n* Any clinically active diagnosed infection requiring systemic antimicrobial therapy, positive microbiologic evidence of infection, or infection-related hospitalization within 30 days prior to study enrollment.\n* Immunosuppression\n* Current use of chemotherapy drugs or active cancer\n* Pregnancy\u002Fbreastfeeding\n* Hospitalized within the past 6 months\n* Allergic\u002Fintolerance to colchicine\n* Use of P-glycoprotein (p-gp) inhibitor (such as Verapamil, Quinidine, Amiodarone, Ritonavir, Lopinavir\u002Fritonavir, Saquinavir, Nelfinavir)\n* Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (such as Ketoconazole, Itraconazole, Posaconazole, Voriconazole, Clarithromycin, Erythromycin)\n* Human immunodeficiency virus (HIV) infection\n* Gout attack ≥ 1 time per year\n* Severe anemia (hemoglobin \\\u003C 8 g\u002Fdl for women and \\\u003C 9 g\u002Fdl for men)\n* eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2\n* uACR \\\u003C200 mg\u002Fg\n* White blood cell count (WBC) \\\u003C3.0 x109\u002FL\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 3 x Upper Limit of Normal (ULN)\n* Total bilirubin \\>2 x ULN\n* Glucose \\>300mg\u002Fdl\n* Uses nicotine products or other recreational drugs\n* Unable to read or speak English\n* Participant in other conflict clinical trial,\n* Unable to complete the study measurements\n* Unable to undergo to computed tomography (CT) or dual-energy X-ray absorptiometry (DXA) scans\n* Unsafe to participate in this study per investigator's judgement.","69 Years",{"count":178,"type":21},[422],"PHASE2","The overall objective of this pilot randomized clinical trial is to determine whether low-dose Colchicine (LoDoCo) improves vascular disease including vascular calcification, peripheral arterial disease (PAD), and chronic kidney disease-mineral and bone disorder (CKD-MBD) biomarkers in patients with chronic kidney disease (CKD) stage 3 over a 12-month intervention period, compared with usual care.\n\nSuccessful completion of this study will generate critical preliminary data to support a larger clinical trial aimed at evaluating inflammation-targeted therapies to mitigate CKD-MBD, including vascular calcification and related PAD, as well as osteoporosis, ultimately reducing cardiovascular events and mortality in patients with CKD. Additionally, this work has the potential to redefine the diagnostic framework for CKD-MBD.",[425,28,396,29,426,427],"Chronic Kidney Disease Mineral and Bone Disorder","Atherosclerotic Cardiovascular Disease (ASCVD)","Chronic Kidney Disease (Stage 3)",[429,430,431,432],"Chronic Kidney Disease","CVD","vascular calcification","Colchicine","2026-06-17",{"date":230,"type":43},{"date":378,"type":21},{"date":76,"type":21},{"name":438,"class":50},"University of Texas Southwestern Medical Center",{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":17,"minAge":369,"maxAge":446,"enrollmentInfo":447,"targetDuration":4,"studyType":22,"phases":449,"briefSummary":450,"conditions":451,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":51},"100633239","moderate-intensity-statin-plus-ezetimibe-in-ckd-and-ascvd-100633239","NCT07524101","Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD","Utilizing Lipid-lowering Therapy With Moderate-intensity Statin Plus Ezetimibe in Chronic Kidney Disease Patients With Concomitant Atherosclerotic Cardiovascular Disease: ULTRA-CKD Trial","Inclusion Criteria:\n\n1. Age 19-85 years.\n2. Chronic kidney disease stage III, IV, or V (CKD-EPI eGFR \\\u003C60 \u002F \\\u003C30 \u002F \\\u003C15 mL\u002Fmin\u002F1.73 m² or on dialysis).\n3. Established ASCVD, meeting at least one of the following:\n\n   * Prior acute coronary syndrome (myocardial infarction or unstable angina).\n   * Stable angina confirmed by imaging studies.\n   * History of coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting).\n   * Peripheral artery disease.\n   * Ischemic stroke or transient ischemic attack.\n\nExclusion Criteria:\n\n1. Baseline LDL cholesterol \\\u003C55 mg\u002FdL in the absence of statin therapy.\n2. Acute liver disease or persistently unexplained serum AST\u002FALT ≥2 × the upper limit of normal.\n3. Allergy or hypersensitivity to statins.\n4. Life expectancy \\\u003C1 year.\n5. Expected inability to complete at least 1 year of follow-up.\n6. Inability to read or understand the informed consent form.","85 Years",{"count":448,"type":21},1952,[24],"The ULTRA-CKD trial is a prospective, randomized, open-label, multicenter trial designed to compare the efficacy and safety of moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy in patients with chronic kidney disease (CKD) and concomitant atherosclerotic cardiovascular disease (ASCVD).\n\nPatients with CKD are at very high risk for ASCVD. In this population, it is important to establish a lipid-lowering strategy that optimizes cardiovascular outcomes while ensuring long-term safety. While high-intensity statins are generally considered as initial treatment option for secondary prevention, the optimal strategy for CKD patients remains to be clinicaly defined. This study aims to evaluate whether the combination of moderate-intensity statin and ezetimibe is non-inferior to high-intensity statin monotherapy in terms of 3-year composite of major adverse cardiovascular events.",[452,453,29,454,400],"Renal Insufficiency","Atherosclerosis","Hypercholesterolemia","2026-06-11",{"date":457,"type":43},"2026-06-16",{"date":459,"type":43},"2026-05-28",{"date":461,"type":21},"2031-01-22",{"name":463,"class":50},"Yonsei University",{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":59,"sex":17,"minAge":369,"maxAge":88,"enrollmentInfo":471,"targetDuration":4,"studyType":22,"phases":472,"briefSummary":468,"conditions":473,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":51},"100639685","phase-1-a-study-to-evaluate-the-safety-and-pharmacokinetics-of-ad-231-compared-to-coadministration-of-ad-231a-ad-231d-and-ad-231c-100639685","NCT07590167","A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 and under 65 years in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",{"count":178,"type":21},[65],[29,28],"2026-05-11",{"date":476,"type":43},"2026-05-15",{"date":478,"type":21},"2026-06",{"date":480,"type":21},"2026-07",{"name":482,"class":79},"Addpharma Inc.",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":17,"minAge":491,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":22,"phases":494,"briefSummary":495,"conditions":496,"keywords":497,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":506,"locationsCount":51},"100619889","llm-comanage-large-language-model-enabled-co-management-of-hypertension-diabetes-and-dyslipidemia-100619889","NCT07350486","LLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia","A Cluster-Randomized Trial of Large Language Model-Enabled Coordinated Management for Hypertension, Diabetes, and Dyslipidemia in Community Settings (LLM-CoManage Trial)","LLM-CoManage","Inclusion Criteria:\n\nParticipating communities must meet all of the following criteria:\n\n* Have a designated community physician responsible for primary care who is capable of using a smartphone with stable internet access for clinical communication and LLM-assisted management;\n* No plan for administrative merger or restructuring within the next three years;\n* Located at least 2 kilometers away from adjacent participating communities (to minimize contamination between clusters).\n\nEligible participants must fulfill all of the following conditions:\n\n* Aged 40 years or older;\n* Uncontrolled hypertension, defined as systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg;\n* Coexisting diabetes (HbA1c ≥ 7.0%) or coexisting dyslipidemia (LDL-C ≥ 3.4 mmol\u002FL\\[130 mg\u002FdL\\]);\n* Able to use a smartphone independently or with assistance from family members;\n* Has resided in the participating community for at least 6 months;\n* Has no plan to relocate in the next 3 years;\n* Enrolled in basic medical insurance for urban and rural residents, employee medical insurance, or the New Rural Cooperative Medical Scheme;\n* Not currently pregnant or planning pregnancy during the study period;\n* Free from malignant tumors and deemed to have a life expectancy of at least 3 years, as judged by study physicians;\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:No specific exclusion criteria.","40 Years",{"count":493,"type":21},6800,[24],"This study aims to evaluate the effectiveness of a large language model (LLM)-supported, community-based integrated management model in improving cardiometabolic multimorbidity control among adults with hypertension and coexisting diabetes or dyslipidemia. Adopting an interventional study design, eligible patients will be recruited to compare the disease control indicators between LLM-assisted management and conventional management, so as to verify the effectiveness and safety of the former.",[28,396,29],[498,499],"Large Language Model","Co-Management","2026-05-09",{"date":502,"type":43},"2026-05-13",{"date":504,"type":21},"2026-06-15",{"date":76,"type":21},{"name":507,"class":50},"First Hospital of China Medical University",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":59,"sex":17,"minAge":369,"maxAge":176,"enrollmentInfo":515,"targetDuration":4,"studyType":22,"phases":516,"briefSummary":517,"conditions":518,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":51},"100638182","phase-1-bioequivalence-study-of-aju-c715-and-c715r-in-healthy-adult-volunteers-100638182","NCT07581028","Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers","An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of \"AJU-C715\" and \"C715R\" in Healthy Adult Volunteers","Inclusion Criteria:\n\n1. Healthy adults aged 19 to less than 60 years at the time of screening\n2. Weight ≥ 50 kg for men or ≥ 45 kg for women, with a calculated body mass index(BMI) of 18 to 30 kg\u002Fm² at the time of screening.\n3. Those who have no congenital chronic disease or chronic disease requiring treatment and who have no pathological symptoms or findings.\n4. Those who are eligible for the clinical trial based on laboratory test results(hematology, blood chemistry, serum, and urine tests) and 12-lead ECG findings during screening.\n5. Those who voluntarily decide to participate and agree to comply with the cautions after hearing and fully understanding the detailed description of this clinical trial.\n6. Those who agree to use highly effective methods of contraception(excluding hormonal methods) to prevent pregnancy, either for themselves or their spouse\u002Fpartner, from the first administration of the investigational medicinal product until one week after the last administration, and who agree not to donate sperm or eggs during this period.\n\nExclusion Criteria:\n\n1. Those who take barbiturate and related (causing induction or inhibition of metabolism) drug within 1 month or the first administration of clinical trial drug within 10 days.\n2. Those who received investigational product or bioequivalence test drug within 6 months before the first administration of clinical trial drug. 3. Those who donated whole blood within 8 weeks, received apheresis within 2 weeks, blood transfusion within 1 month or can't refrain from donating blood from the time of written consent until the end of the study.\n\n4\\. Those who has a history of gastrointestinal disease or surgery which may affect the absorption of the drug.\n\n5\\. Those who exceeding an alcohol consumption criteria Alcohol: Men - 21 glass\u002Fweek, Women - 14 glass\u002Fweek (1 glass: Soju 50 mL, Beer 250mL or liquor: 30mL), Smoke: 20 cigarettes\u002Fday.\n\n6\\. Those who has under\n\n* Those who are hypersensitive to component of the Investigational product and have the medical history\n* Those with active liver disease or persistent elevation of aminotransferase levels of unknown\n* Those taking cyclosporin\n* Those with Myopathy\n* Those with severe Renal Impairment due to Renal Failure\n* Those who has Genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption 7. Those who has a history of mental illness. 8. Those who are deemed unfit by the investigators to participate in the clinical trial for other reasons.\n\n  9\\. Women who are pregnant or who may be pregnant and breastfeed.",{"count":178,"type":21},[65],"To Evaluate the Safety and Pharmacokinetics of \"AJU-C715\" and \"C715R\" in Healthy Adults.",[519,29],"Hypercholerolemia","2026-05-06",{"date":45,"type":43},{"date":523,"type":21},"2026-08-07",{"date":525,"type":21},"2026-08-24",{"name":527,"class":79},"AJU Pharm Co., Ltd.",{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":17,"minAge":243,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":22,"phases":536,"briefSummary":538,"conditions":539,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":547,"locationsCount":51},"100467335","phase-4-choline-fenofibrate-and-carotid-atherosclerosis-in-patients-with-type-2-diabetes-and-combined-dyslipidemia-100467335","NCT05365425","Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia","Effect of Choline Fenofibrate on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined Dyslipidemia","Inclusion Criteria:\n\n* Type 2 diabetes under treatment with HbA1c 6.0-10.0% at screening visit\n* Male or female of 20 years or over\n* Mixed dyslipidemia: triglyceride 200\\~499 mg\u002FdL, HDL-cholesterol male ≤45 mg\u002FdL or female ≤50 mg\u002FdL\n* Identified carotid artery plaque: carotid intima-media thickness (cIMT) ≥ 1.0 mm\n* Creatinine ≤1.8 mg\u002FdL\n\nExclusion Criteria:\n\n* Dyslipidemia which requires other therapy: triglyceride ≥500 mg\u002FdL or LDL-cholesterol ≥190 mg\u002FdL\n* Uncontrolled hypertension\n* Severe renal dysfunction\n* GOT\u002FGPT \\>120\u002F120 or chronic liver disease\n* Pregnant or childbearing woman who does not have enough contraception\n* Changes of medication related to chronic diseases (diabetes, hypertension, dyslipidemia, etc.) within 3 months\n* Other antiplatlet medication such as cilostazol, clopidogrel (except aspirin)",{"count":5,"type":21},[537],"PHASE4","This is a randomized controlled study to assess the effect of choline fenofibrate compared with policosanol in Korean T2DM patients with asymptomatic atherosclerosis.",[29,453,540],"Diabetes Mellitus, Type 2","2026-05-02",{"date":543,"type":43},"2026-05-05",{"date":545,"type":43},"2023-06-01",{"date":76,"type":21},{"name":548,"class":50},"Seoul National University Bundang Hospital",{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":17,"minAge":556,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":22,"phases":559,"briefSummary":560,"conditions":561,"keywords":562,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":51},"100635429","goal-commitment-and-proactive-health-behavior-in-chronic-disease-patients-100635429","NCT07552571","Goal Commitment and Proactive Health Behavior in Chronic Disease Patients","Evolution and Driving Mechanism of Proactive Health Behavior in Chronic Disease Patients Based on Goal Commitment","Inclusion Criteria:\n\n* Residents living in the study area for at least 1.5 years\n* Diagnosed with at least one chronic disease, including hypertension, diabetes mellitus, or dyslipidemia\n* Conscious and able to communicate effectively\n* Educational level of primary school or above\n* Able to use a smartphone and common mobile applications (e.g., WeChat)\n* Willing to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Non-residents of the study area\n* Unable to participate in group-based intervention activities\n* Currently hospitalized\n* Diagnosed with severe cognitive impairment, dementia, or psychiatric disorders\n* Participants with severe comorbidities that may interfere with study participation","45 Years",{"count":558,"type":21},600,[24],"Chronic diseases such as hypertension, diabetes, and dyslipidemia are major contributors to mortality and healthcare burden worldwide. Despite high awareness of health risks, many patients fail to adopt proactive health behaviors due to behavioral inertia and a gap between knowledge and action.\n\nThis study aims to investigate the evolution and driving mechanisms of proactive health behavior in patients with chronic diseases based on goal commitment theory. By integrating prospect theory and evolutionary game theory, this study will explore how behavioral strategies evolve under different levels of goal commitment.\n\nIn addition, a behavioral intervention based on the Stimulus-Organism-Response (SOR) model will be developed to enhance patient activation and promote adherence to proactive health behaviors. A parallel controlled intervention study will be conducted to evaluate the effectiveness of the goal commitment-based intervention.\n\nThe findings of this study are expected to provide theoretical and practical evidence to improve chronic disease management and promote proactive health behaviors.",[28,94,29],[563,564,565,566,567,568],"Proactive Health Behavior","Goal Commitment","Chronic Disease Management","Behavioral Intervention","Patient Activation","SOR Model","2026-04-30",{"date":520,"type":43},{"date":572,"type":43},"2025-05-15",{"date":574,"type":21},"2028-12-31",{"name":576,"class":50},"Xiong Juyang",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":581,"acronym":582,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":22,"phases":586,"briefSummary":587,"conditions":588,"keywords":593,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":51},"100585860","the-switch-substitution-of-high-with-low-ultra-processed-soy-protein-foods-in-a-guideline-based-diet-intervention-for-cardiometabolic-health-trial-100585860","NCT06907862","The SWITCH (Substitution of High With Low Ultra-processed Soy Protein Foods In a Guideline-based Diet inTervention for Cardiometabolic Health) Trial","SWITCH","Inclusion Criteria:\n\n* Obesity (BMI and waist circumference using sex and ethnic-specific thresholds for obesity and significant abdominal adiposity)\n* adults (≥18years)\n* hypertension (SBP 120-160 mmHg)\n* on stable antihypertensive, antihyperglycemic, antihyperlipidemic, or anti-obesity medications (≥3-months)\n* not planning new weight loss for the duration of the trial\n* 50% living with type 2 diabetes, HbA1c 6.5-9.0%\n\nExclusion Criteria:\n\n* Individuals with a history of major cardiovascular events in the last year (stroke or myocardial infarction)\n* type 1 diabetes diagnosis\n* recent weight loss or weight gain (≥5% over \\\u003C6 months)\n* current treatment with insulin\n* eating disorders; substance abuse disorders\n* serious depression or psychiatric disorders\n* bariatric or recent surgery (\\\u003C6 months)\n* uncontrolled hypertension (SBP\u002FDBP \\>160\u002F100 mmHg)\n* angina pectoris\n* gastrointestinal and malabsorption disorders (i.e. inflammatory bowel disease, celiac), pancreatitis, chronic kidney or liver disease, cardiac condition that compromises normal function (e.g. mitral valve disease, heart failure), major disability or disorder requiring continuous medical attention.\n* herb or supplement use that may affect primary outcome.\n* alcohol use \\>3 drinks\u002Fday; participation in another trial.\n* allergies\u002Fintolerances to soy; allergies\u002Fintolerances to tree nuts, peanuts and seeds (the combination of all 3).\n* chronic or prescribed use of certain medications including prescription high dose NSAIDs, antacids, warfarin, medications affecting NO synthesis (i.e. sildenafil, organic nitrates, etc.)\n* acute or chronic infection (e.g. active HIV, TB, COVID-19, chronic inflammatory infections)\n* chronic inflammatory condition (such as rheumatoid arthritis)\n* use of antibiotics within 3-months of the study start",{"count":585,"type":21},300,[24],"This is a randomized, controlled, parallel study with 3 experimental arms aimed to assess the effect of a digital dietary intervention (web-based app, online behavior change curriculum) enhanced with 10 servings of vegetables and fruit (5 as dietary advice within the app, 5 within a dehydrated vegetable and fruit blend), with or without high Ultra Processed Food (UPF) soy-containing proteins compared to standard of care (usual care) on systolic blood pressure (SBP; primary outcome), and other key cardiometabolic endpoints over 12-weeks in adults living with hypertension and obesity, 50% with type 2 diabetes. The main questions this study aims to answer are:\n\n1. Are nutrient-dense, high-UPF soy-protein foods similar (non-inferior) to low-UPF soy-protein foods in the context of a guidelines-based diet in their effect on blood pressure and other cardiometabolic risk factors?\n2. Does an enhanced digital dietary intervention lead to meaningful reductions in blood pressure and other cardiometabolic risk factors compared to standard of care?\n\nParticipants who are eligible and consent to be part of this study will be randomized to one of the following groups: 1) Active treatment (high-UPF soy-containing enhanced digital dietary intervention), 2) Reference treatment (low-UPF soy-containing enhanced digital dietary intervention), or 3) Control (standard of care).\n\nParticipant Requirements:\n\nDuring the 12-week intervention, all participants will be required to attend in-person clinic visits at baseline (week 0), week 8 and 12.\n\nBaseline Visit (Week 0): Participants will be asked to arrive in a fasted state (no food or beverages, except water, for 10-12 hours before the visit).\n\n* Undergo various assessments, including anthropometric measurements, office blood pressure readings, and blood sampling (via a capillary finger prick and blood sample taken by the study nurse).\n* Review the 7-day food records completed using the Keenoa mobile app one week prior to clinic visit.\n* Bring fecal and urine samples from home.\n* Complete and review all questionnaires received via email one week prior.\n\nTelephone Check-in (Week 1):\n\nOne week after beginning the study, the study staff will call participants to check in on how participants are following the protocol and answer any questions.\n\nMid-Study Visit (Week 8): Participants will be asked to arrive in a fasted state (no food or beverages, except water, for 10-12 hours before the visit).\n\n* Have their office blood pressure and anthropometric measurements taken.\n* Complete and review all questionnaires received via email one week prior\n* Review the 3-day food records completed using the Keenoa mobile app one week prior to clinic visit.\n\nFinal Study Visit (Week 12): Participants will be asked to arrive in a fasted state (no food or beverages, except water, for 10-12 hours before the visit).\n\n* Undergo various assessments, including anthropometric measurements, office blood pressure readings, and blood sampling (via a capillary finger prick and blood sample taken by the study nurse).\n* Review the 7-day food records completed using the Keenoa mobile app one week prior to clinic visit.\n* Bring fecal and urine samples from home.\n* Complete and review all questionnaires received via email one week prior.\n\nThroughout the study, participants will be asked to continue their usual lifestyle and physical activity.\n\nAdditional Requirements for Treatment Groups:\n\nParticipants randomized to the active and reference treatment groups will also be required to:\n\n* Incorporate a study vegetable and fruit blend (provided) into their daily diet for the full 12 weeks\n* Consume soy products categorized as either high ultra processed soy foods at least 4 servings per day, including at least 2 servings of ultra processed soy milk and 2 servings of other soy-based products (e.g., soy yogurt, soy burgers, or soy ground round) or non-ultra processed soy foods at least 4 servings per day, including at least 2 servings of minimally processed soy milk, 1 serving of edamame or roasted soy nuts, and 1 serving of tofu or tempeh\n* Participate in the digital dietary intervention, which includes: a health app, 7-day Kickstart Package, weekly text message support, and a 7-session online interactive program designed based on behaviour change theory\n* Attend a virtual focus group at Week 4 and complete an online feedback questionnaire",[589,590,29,28,591,592],"Hypertension in Type 2 Diabetes","Diabetes Mellitus Type 2","Metabolic Health","Cardiovascular Risk Factors",[402,28,594,595,596,597],"Cardiometabolic health","Ultra processed food","technology-based dietary intervention","dehydrated vegetable and fruit blend","2026-04-27",{"date":600,"type":43},"2026-05-04",{"date":602,"type":43},"2025-08-06",{"date":604,"type":21},"2028-06-30",{"name":606,"class":50},"University of Toronto",{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":613,"eligibilityCriteria":614,"healthyVolunteers":12,"sex":17,"minAge":491,"maxAge":615,"enrollmentInfo":616,"targetDuration":4,"studyType":22,"phases":618,"briefSummary":619,"conditions":620,"keywords":621,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":51},"100635932","supplementation-with-salicornia-extract-rich-in-polyphenols-b-salicornia-to-improve-vascular-health-in-patients-with-dyslipidemia-who-are-not-candidates-for-drug-treatment-low-to-moderate-risk-100635932","NCT07559110","Supplementation With Salicornia Extract Rich in Polyphenols (B-Salicornia) to Improve Vascular Health in Patients With Dyslipidemia Who Are Not Candidates for Drug Treatment (Low to Moderate Risk)","Prospective, Randomized, Open-label, Parallel-Group Pilot Study Compared With Usual Medical Practice and Blinded Analysis (PROBE), to Evaluate the Effect and Safety of Administering a Food Supplement Based on Halophyte Plant Extracts in Patients With Newly Diagnosed Dyslipidemia Who do Not Have an Indication for Medical Treatment.","SALICOL","Inclusion Criteria:\n\n* Participants aged 40 to 65\n* Newly diagnosed dyslipidemia (two years) with SCORE ≥1 - \\\u003C5 (LDL 116 - \\\u003C190 mg\u002FdL): Moderate Risk\n* No indication for pharmacological treatment in primary prevention.\n* Possibility of performing analytical controls at the beginning\u002Fend of the study.\n* Willingness and capacity to give informed consent.\n\nExclusion Criteria:\n\n* Participants with vascular risk requiring pharmacological treatment or high\u002Fvery high vascular risk.\n* Participants in secondary prevention.\n* Hyperthyroidism according to the researcher's criteria.\n* Taking vitamin B supplements and\u002For supplements containing polyphenols in the 30 days prior to the screening visit (at the researcher's discretion).\n* Serious illness with a life expectancy of less than three months.\n* Known allergies or intolerance to halophytic plants.\n* Pregnant or breastfeeding women.\n* Presence of active neoplastic disease.\n* Having participated in another clinical trial with medicines in the 30 days prior to the screening visit, or intending to do so during your participation in this study.\n* Regular consumption of halophyte plants.\n* Participants who, in the researcher's opinion, are not able to comply with the study protocol.","65 Years",{"count":617,"type":21},250,[24],"The aim of this clinical trial is to evaluate the ability of a dietary supplement based on salicornia extracts and B vitamins (B-Salicornia) to modulate lipid levels in a population with newly diagnosed dyslipidemia who are not eligible for medical treatment.",[29],[622,623,624],"food supplement","polyphenol","Dyslipidaemia","2026-04-23",{"date":569,"type":43},{"date":628,"type":21},"2026-05",{"date":630,"type":21},"2027-05",{"name":632,"class":50},"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla",{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":637,"acronym":4,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":17,"minAge":639,"maxAge":640,"enrollmentInfo":641,"targetDuration":4,"studyType":22,"phases":642,"briefSummary":643,"conditions":644,"keywords":645,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":648,"lastUpdatePostDateStruct":649,"startDateStruct":651,"completionDateStruct":652,"leadSponsor":654,"locationsCount":51},"100634847","impact-of-a-produce-prescription-program-and-nutrition-education-intervention-on-cardiovascular-health-in-youth-100634847","NCT07545005","Impact of a Produce Prescription Program and Nutrition Education Intervention on Cardiovascular Health in Youth","Inclusion Criteria:\n\n1. Ages 2-17 years (with caregiver)\n2. Patient at BCH AND\n3. Underlying cardiovascular risk condition:\n\n   1. High Blood Pressure\n   2. Dyslipidemia\n   3. Elevated BMI AND\n4. Enrolled in or eligible for a Medicaid Healthcare plan OR\n5. SNAP eligible\n\nExclusion Criteria:\n\n1\\. Conditions that require urgent treatment:\n\n1. Hypertensive Urgency\n2. Hypertensive Emergency\n3. Dialysis-dependent kidney disease","2 Years","17 Years",{"count":150,"type":21},[24],"This study will assess the effect of a produce prescription program combined with nutritional classes on short and longer-term cardiovascular health in a cohort of children at risk for cardiovascular disease. The communities of interest we aim to engage in this project are children and adolescents in Boston and the surrounding areas with acquired cardiovascular risk factors of high blood pressure or abnormal cholesterol that are cared for at Boston Children's Hospital and who qualify or are enrolled in (1) Benefits under the Food and Nutrition Act of 2008; (2) medical assistance under a State plan or a waiver of such a plan under title XIX of the Social Security. This project will create a first-time partnership between the BCH cardiology department and a produce prescription program (Fresh Connect) and will introduce services and resources not previously available to these patients. Participants will be able to use the Fresh Connect pre-paid debit card to purchase fruits and vegetables of their choosing from numerous local food retailers convenient to their own neighborhood. We currently do not have any healthcare-led social support networks amongst patients seen for evaluation of cardiovascular risk factors. As such, this project will introduce a new community-building resource amongst our patients by creating interactive, culturally tailored nutritional classes. The virtual nutrition classes will offer a friendly, interactive environment in which patients and families can share their experiences and learn from each other and from our dietitians. By fostering these relationships amongst patients\u002Fcaregivers, we hope to decrease the stigma some families feel when their child is diagnosed with hypertension or abnormal cholesterol.",[29,28,183],[646,647],"Food insecurity","food is medicine","2026-04-16",{"date":650,"type":43},"2026-04-22",{"date":269,"type":21},{"date":653,"type":21},"2029-04-01",{"name":655,"class":50},"Boston Children's Hospital",{"id":657,"slug":658,"hasResults":12,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":662,"eligibilityCriteria":663,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":664,"enrollmentInfo":665,"targetDuration":4,"studyType":22,"phases":666,"briefSummary":667,"conditions":668,"keywords":669,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":685,"lastUpdatePostDateStruct":686,"startDateStruct":688,"completionDateStruct":689,"leadSponsor":691,"locationsCount":51},"100632583","effect-of-compound-cardiol-forte-on-lipid-and-glycemic-parameters-in-low-cardiovascular-risk-individuals-100632583","NCT07515573","Effect of Compound (Cardiol Forte) on Lipid And Glycemic Parameters in Low Cardiovascular Risk Individuals","A Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Parallel-Group Clinical Trial With an Open-Label Extension to Evaluate the Effects of a Combination Dietary Supplement (Cardiol Forte) on Lipid and Glycemic Parameters in Subjects at Low Cardiovascular Risk With Suboptimal Cholesterol Levels","CLARISKI","Inclusion Criteria:\n\n* Male or female aged 18 to 79 years\n* Individuals in primary cardiovascular prevention\n* Estimated 10-year cardiovascular risk \\\u003C10%\n* Screening non-HDL-C between 140 and 220 mg\u002FdL, or screening LDL-C between 110 and 190 mg\u002FdL\n* Ability to communicate adequately, to be understood, and to comply with the study requirements\n* Willingness to participate in the study and provision of written, signed, and dated informed consent\n\nExclusion Criteria:\n\n* Triglycerides \\>400 mg\u002FdL at screening\n* Type 1 or type 2 diabetes mellitus\n* Body mass index \\>35 kg\u002Fm²\n* Current treatment with lipid-lowering drugs or use of dietary supplements active on lipid metabolism\n* Antihypertensive treatment not stabilized for at least 3 months\n* Known clinically significant alterations of thyroid, hepatic, and\u002For renal function\n* Women of childbearing potential not using adequate contraceptive methods\n* Pregnancy or breastfeeding\n* Any medical or surgical condition that, in the investigator's judgment, could make adherence to the protocol difficult or inconsistent, compromise participant safety, or interfere with study completion\n* Known intolerance or hypersensitivity to any component of the study products","79 Years",{"count":246,"type":21},[24],"This study will evaluate the effects of a combination dietary supplement, Cardiol Forte, on lipid and glycemic parameters in adults at low cardiovascular risk with suboptimal cholesterol levels. After a 14- to 28-day run-in period with standardized dietary and behavioral instructions, 50 participants will be randomized in a 1:1 ratio to receive either Cardiol Forte or matching placebo for 8 weeks under double-blind conditions. After completion of the double-blind phase, all participants will receive Cardiol Forte for an additional 8 weeks in an open-label extension. The primary objective is to compare the change in non-high-density lipoprotein cholesterol (non-HDL-C) from baseline to Week 8 between Cardiol Forte and placebo. Secondary objectives include evaluation of other lipid parameters, fasting plasma glucose, Omega-3 Index, selected inflammatory and liver-related markers, and endothelial reactivity.",[29],[670,29,671,672,673,674,675,676,677,678,679,680,681,682,683,684],"Cardiol Forte","non-HDL cholesterol","Glycemic profile","Cardiovascular prevention","Low cardiovascular risk","Eicosapentaenoic acid","EPA","Docosahexaenoic acid","DHA","Artichoke","Bergamot","Hydroxytyrosol","Coenzyme Q10","Folic acid","Vitamin E","2026-04-15",{"date":687,"type":43},"2026-04-20",{"date":600,"type":21},{"date":690,"type":21},"2028-05-04",{"name":692,"class":79},"U.G.A. Nutraceuticals",{"id":694,"slug":695,"hasResults":12,"nctId":696,"briefTitle":697,"officialTitle":698,"acronym":4,"eligibilityCriteria":699,"healthyVolunteers":59,"sex":17,"minAge":700,"maxAge":4,"enrollmentInfo":701,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":702,"conditions":703,"keywords":708,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":685,"lastUpdatePostDateStruct":716,"startDateStruct":717,"completionDateStruct":718,"leadSponsor":720,"locationsCount":51},"100631593","validation-of-remote-photoplethysmography-rppg-derived-cardiovascular-parameters-against-standard-clinical-measurements-and-risk-scores-in-a-community-100631593","NCT07502703","Validation of Remote Photoplethysmography (rPPG)-Derived Cardiovascular Parameters Against Standard Clinical Measurements and Risk Scores in a Community","Validation of Remote Photoplethysmography (rPPG)-Derived Cardiovascular Parameters Against Standard Clinical Measurements and Risk Scores in a Community-Based Population in Semanan, Jakarta","Inclusion Criteria:\n\n1. Adults aged ≥30 years\n2. Willing to participate and provide informed consent\n3. Able to undergo face scan, clinical examination, and laboratory testing\n\nExclusion Criteria:\n\n1. Facial abnormalities interfering with rPPG signal acquisition\n2. Inability to remain still during measurement\n3. Severe clinical instability\n4. Incomplete key variables","30 Years",{"count":585,"type":21},"The goal of this observational study is to evaluate whether a contactless camera-based technology, called remote photoplethysmography (rPPG), can accurately measure cardiovascular parameters and estimate cardiovascular risk in adults aged 30 years and older living in a community setting in Semanan, Jakarta. This study aims to determine if rPPG can be used as a simple and accessible tool for early cardiovascular screening.\n\nThe main questions it aims to answer are:\n\n1. Do cardiovascular parameters measured using rPPG (such as blood pressure, heart rate, and cardiac workload) agree with standard clinical measurements?\n2. Do cardiovascular risk estimates generated by rPPG (such as ASCVD risk and Framingham heart age) correspond to risk calculations obtained using conventional clinical and laboratory methods?\n\nResearchers will compare results obtained from rPPG-based facial video scans with results from standard medical assessments, including blood pressure measurements, heart rate evaluation, and laboratory tests for cholesterol levels, to determine the level of agreement and accuracy.\n\nParticipants will:\n\n1. Undergo a short facial video scan (approximately 30-60 seconds) using an rPPG-based system\n2. Receive standard clinical assessments, including blood pressure and heart rate measurements\n3. Provide basic health information (such as age, sex, smoking status, and treatment history) Undergo simple laboratory testing for cholesterol levels\n\nThis study is expected to help determine whether rPPG can be used as a reliable, non-invasive, and scalable screening tool for cardiovascular risk in community and primary healthcare settings.",[29,704,705,706,28,707],"Angina (Stable)","Coronary Artery Disease (CAD)","Heart Disease","Diabetes (DM)",[709,710,711,712,713,714,715],"remote photoplethysmography","rPPG","cardiovascular risk","ASCVD","Framingham score","digital health","screening tool",{"date":687,"type":43},{"date":625,"type":21},{"date":719,"type":21},"2026-12-30",{"name":721,"class":50},"Tarumanagara University"]